Etelcalcetide: What we know eight years since its approval

IF 2 4区医学 Q2 UROLOGY & NEPHROLOGY

Nefrologia Pub Date : 2025-02-01 DOI:10.1016/j.nefro.2024.09.004

Pedro Freitas , Luciano Pereira

{"title":"Etelcalcetide: What we know eight years since its approval","authors":"Pedro Freitas , Luciano Pereira","doi":"10.1016/j.nefro.2024.09.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction and objectives</h3><div>The impact of etelcalcetide on patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) has been studied since its introduction in 2016/2017. However, only a handful of studies reported clinically relevant outcomes. This narrative review aims to summarize the published data about etelcalcetide, focusing on biochemical, cardiovascular (CV) and bone endpoints, as well as adverse effects and all-cause mortality.</div></div><div><h3>Materials and methods</h3><div>A literature review of the use of etelcalcetide in hemodialysis patients with SHPT was conducted. Several sources were used, such as PubMed, Google Scholar and Cochrane Library.</div></div><div><h3>Results</h3><div>Regarding bone and mineral metabolism, etelcalcetide is effective in reducing serum levels of parathormone (PTH), calcium, phosphate and fibroblast growth factor 23 (FGF23). Preliminary data have highlighted its role in reducing bone turnover and improving mineralization and preservation of bone structure, indicating a possible positive impact on renal osteodystrophy. From a CV perspective, etelcalcetide is associated with a significant reduction in left ventricular hypertrophy. In addition, etelcalcetide reduces FGF23 and increases sclerostin serum levels. This data suggests a possible CV beneficial effect.</div></div><div><h3>Conclusions</h3><div>Etelcalcetide is effective in controlling SHPT. Promising data is available for some bone and surrogate cardiovascular endpoints, suggesting a possible beneficial effect. There is a lack of studies specifically designed to evaluate its role in reducing fractures, CV and all-cause mortality.</div></div>","PeriodicalId":18997,"journal":{"name":"Nefrologia","volume":"45 2","pages":"Pages 116-134"},"PeriodicalIF":2.0000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nefrologia","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0211699524000900","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and objectives

The impact of etelcalcetide on patients with chronic kidney disease (CKD) and secondary hyperparathyroidism (SHPT) has been studied since its introduction in 2016/2017. However, only a handful of studies reported clinically relevant outcomes. This narrative review aims to summarize the published data about etelcalcetide, focusing on biochemical, cardiovascular (CV) and bone endpoints, as well as adverse effects and all-cause mortality.

Materials and methods

A literature review of the use of etelcalcetide in hemodialysis patients with SHPT was conducted. Several sources were used, such as PubMed, Google Scholar and Cochrane Library.

Results

Regarding bone and mineral metabolism, etelcalcetide is effective in reducing serum levels of parathormone (PTH), calcium, phosphate and fibroblast growth factor 23 (FGF23). Preliminary data have highlighted its role in reducing bone turnover and improving mineralization and preservation of bone structure, indicating a possible positive impact on renal osteodystrophy. From a CV perspective, etelcalcetide is associated with a significant reduction in left ventricular hypertrophy. In addition, etelcalcetide reduces FGF23 and increases sclerostin serum levels. This data suggests a possible CV beneficial effect.

Conclusions

Etelcalcetide is effective in controlling SHPT. Promising data is available for some bone and surrogate cardiovascular endpoints, suggesting a possible beneficial effect. There is a lack of studies specifically designed to evaluate its role in reducing fractures, CV and all-cause mortality.

查看原文本刊更多论文

艾替卡肽：我们所知道的，自从它被批准以来已经八年了

自2016/2017年etelcalcetide引入以来，一直在研究其对慢性肾脏疾病（CKD）和继发性甲状旁腺功能亢进（SHPT）患者的影响。然而，只有少数研究报告了临床相关的结果。这篇叙述性综述旨在总结已发表的关于依替卡肽的数据，重点是生化、心血管（CV）和骨骼终点，以及不良反应和全因死亡率。材料与方法回顾性分析了依替卡肽在血液透析合并SHPT患者中的应用。使用了几个来源，如PubMed，谷歌Scholar和Cochrane Library。结果在骨和矿物质代谢方面，依替卡尔肽能有效降低血清甲状旁腺激素（PTH）、钙、磷酸盐和成纤维细胞生长因子23 （FGF23）水平。初步数据强调了其在减少骨转换和改善矿化和骨结构保存方面的作用，表明其可能对肾性骨营养不良有积极影响。从心血管的角度来看，依替卡肽与左心室肥厚的显著减少有关。此外，依替卡尔肽降低FGF23并增加血清硬化蛋白水平。这一数据表明可能存在CV有益效应。结论塞替卡肽能有效控制SHPT。有希望的数据可用于一些骨骼和替代心血管终点，表明可能有益的效果。缺乏专门设计的研究来评估其在降低骨折、心血管疾病和全因死亡率方面的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nefrologia 医学-泌尿学与肾脏学

CiteScore

3.40

自引率

7.70%

发文量

148

审稿时长

47 days

期刊介绍： Nefrología is the official publication of the Spanish Society of Nephrology. The Journal publishes articles on basic or clinical research relating to nephrology, arterial hypertension, dialysis and kidney transplants. It is governed by the peer review system and all original papers are subject to internal assessment and external reviews. The journal accepts submissions of articles in English and in Spanish languages.